Naoki Misumida1, Kishore Harjai2, Steven Kernis3, Yumiko Kanei4. 1. Department of Internal Medicine, Mount Sinai Beth Israel, New York, NY, USA misumidanaoki@gmail.com. 2. Department of Cardiology, Geisinger Clinic, Wilkes-Barre, PA, USA. 3. Department of Cardiology, Lourdes Medical Center, Cherry Hill NJ, USA. 4. Department of Cardiology, Mount Sinai Beth Israel, New York, NY, USA.
Abstract
BACKGROUND: The effect of oral beta-blocker therapy on long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who are treated with primary percutaneous coronary intervention (PCI) and who have preserved left ventricular ejection fraction (LVEF) remains unclear. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies evaluating the effect of oral beta-blocker therapy in patients with STEMI who underwent primary PCI and who had preserved LVEF. The primary outcome was all-cause mortality. Randomized controlled trials and the observational studies that reported an adjusted hazard ratio (or hazard ratio in the propensity score-matched patients) with follow-up duration equal to or more than 6 months were included. Pooled hazard ratio with 95% confidence interval (CI) was calculated using a random effect model. RESULTS: No randomized controlled trials met the inclusion criteria. Seven observational studies totaling 10 857 patients met the inclusion criteria. Follow-up duration ranged from 6 months to 5.2 years. Preserved LVEF was defined as 40% in 4 studies and 50% in 3 studies. Based on the pooled estimate, oral beta-blocker therapy was associated with a reduction in all-cause mortality (combined hazard ratio 0.79, 95% CI 0.65-0.97). CONCLUSION: This meta-analysis demonstrates that oral beta-blocker therapy is associated with decreased all-cause mortality in patients with STEMI who are treated with primary PCI and who have preserved LVEF. This supports the current American College of Cardiology Foundation/American Heart Association 2013 Guideline for the Management of STEMI.
BACKGROUND: The effect of oral beta-blocker therapy on long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who are treated with primary percutaneous coronary intervention (PCI) and who have preserved left ventricular ejection fraction (LVEF) remains unclear. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies evaluating the effect of oral beta-blocker therapy in patients with STEMI who underwent primary PCI and who had preserved LVEF. The primary outcome was all-cause mortality. Randomized controlled trials and the observational studies that reported an adjusted hazard ratio (or hazard ratio in the propensity score-matched patients) with follow-up duration equal to or more than 6 months were included. Pooled hazard ratio with 95% confidence interval (CI) was calculated using a random effect model. RESULTS: No randomized controlled trials met the inclusion criteria. Seven observational studies totaling 10 857 patients met the inclusion criteria. Follow-up duration ranged from 6 months to 5.2 years. Preserved LVEF was defined as 40% in 4 studies and 50% in 3 studies. Based on the pooled estimate, oral beta-blocker therapy was associated with a reduction in all-cause mortality (combined hazard ratio 0.79, 95% CI 0.65-0.97). CONCLUSION: This meta-analysis demonstrates that oral beta-blocker therapy is associated with decreased all-cause mortality in patients with STEMI who are treated with primary PCI and who have preserved LVEF. This supports the current American College of Cardiology Foundation/American Heart Association 2013 Guideline for the Management of STEMI.
Authors: Anna Meta Dyrvig Kristensen; Ann Bovin; Ann Dorthe Zwisler; Charlotte Cerquira; Christian Torp-Pedersen; Hans Erik Bøtker; Ida Gustafsson; Karsten Tange Veien; Kristian Korsgaard Thomsen; Michael Hecht Olsen; Mogens Lytken Larsen; Olav Wendelboe Nielsen; Per Hildebrandt; Sussie Foghmar; Svend Eggert Jensen; Theis Lange; Thomas Sehested; Tomas Jernberg; Dan Atar; Borja Ibanez; Eva Prescott Journal: Trials Date: 2020-05-23 Impact factor: 2.279
Authors: João André Ferreira; Rui Miguel Baptista; Sílvia Reis Monteiro; Lino Manuel Gonçalves Journal: Medicine (Baltimore) Date: 2021-01-22 Impact factor: 1.889